Substrate specificity and inhibition studies of human serotonin N-acetyltransferase.
Level 5 - mechanism / opinion, no new human data
In vitro bench research and molecular modeling without human participants (CEBM Level 5).
PubMed 10722724 · doi:10.1074/jbc.275.12.8794
What was done
The human cloned serotonin N-acetyltransferase (AANAT) was expressed in bacteria, purified, cleaved, and enzymatically characterized. Substrate specificity was evaluated across natural and synthetic arylethylamines, pharmacological bioamines, and acyl homologs of acetyl-CoA using a high-performance liquid chromatography assay with radiochemical detection of N-[(3)H]acetylarylethylamine. Peptide combinatorial libraries of tri-, tetra-, and pentapeptides were screened for inhibitors, accompanied by an in silico modeling study based on human AANAT crystal coordinates.
What was found
The abstract does not report specific numerical values such as binding constants, Km, Vmax, or Ki figures. It reports that AANAT showed broad substrate recognition for arylethylamines (including phenyl-, naphthyl-, benzothienyl-, and benzofuranyl-ethylamine derivatives). Among screened pharmacological bioamines, only tranylcypromine functioned as a substrate. Several peptides demonstrated low micromolar inhibitory potency, and specific amino acid residues of the pentapeptide inhibitor S 34461 were identified interacting with the cosubstrate-binding site.
Why it matters
This study maps the substrate tolerance and inhibitor binding properties of human AANAT, clarifying structural interactions for the rate-limiting enzyme in melatonin biosynthesis.
Limits
This is an in vitro biochemical study using recombinant enzyme alongside in silico docking, with no cellular or in vivo human physiological data. Exact numerical kinetic constants and selectivity metrics against related human transferases are not provided in the abstract.
Cited by
- supports Coenzyme A is biochemically required for the synthesis of acetylcholine, cortisol, and melatonin.